Revel Pharmaceuticals
Kevin Desai is the Head of Enzyme Engineering at Revel Pharmaceuticals, where Kevin engineers enzymes to remove molecular damage associated with aging. Prior to this, Kevin worked as a Staff Scientist and Senior Scientist at Encodia, Inc., leading the Enzyme Engineering program. Desai holds a PhD in Biochemistry from Florida State University and completed a Postdoc in Biochemistry at the University of Wisconsin-Madison.
Revel Pharmaceuticals
1 followers
Revel develops therapeutics for multiple diseases of aging including osteoarthritis, kidney disease, cardiovascular disease, skin aging, and complications of diabetes. It is commercializing therapeutic enzymes to degrade age-associated molecule damage.